This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Heat Biologics
ClinicalTrials.gov Identifier:
NCT02010203
First received: December 5, 2013
Last updated: April 21, 2017
Last verified: April 2017
December 5, 2013
April 21, 2017
December 2013
April 2017   (Final data collection date for primary outcome measure)
  • Phase 1: Safety and tolerability [ Time Frame: Up to 3 years ]
  • Phase 2: 1-year Disease-Free Survival [ Time Frame: One year ]
  • Phase 1: Immune response [ Time Frame: Up to 3 years ]
    Immunologic response via intracellular cytokine staining (ICS) by flow cytometry and/or enzyme-linked immunosorbent spot (ELISPOT) on CD8+ cells after receiving 6 vaccine doses.
  • Phase 2: Time to Recurrence [ Time Frame: Up to 3 years ]
Complete list of historical versions of study NCT02010203 on ClinicalTrials.gov Archive Site
  • Proportion of patients with recurrence at 3, 6, 12, 18, and 24 months [ Time Frame: Up to 2 years ]
  • Proportion of patients with progressive disease at 3, 6, 12, 18, and 24 months [ Time Frame: Up to 2 years ]
  • Disease-free survival at 3, 6, 18, and 24 months [ Time Frame: Up to 2 years ]
  • Overall disease-free survival [ Time Frame: Up to 3 years ]
  • Overall survival [ Time Frame: Up to 3 years ]
  • Proportion of patients undergoing repeat transurethral resection of bladder tumor (TURBT) by 12 and 24 months [ Time Frame: Up to 2 years ]
  • Proportion of patients undergoing cystectomy by 12 and 24 months [ Time Frame: Up to 2 years ]
  • Immunologic response of PBMCs via intracellular cytokine staining (ICS) by flow cytometry and/or enzyme-linked immunosorbent spot (ELISPOT) on CD8+ cells after HS-410 vaccination as compared to baseline. [ Time Frame: Up to 2 years ]
  • Immunologic response of peripheral blood mononuclear cells (PBMCs) and stimulation analysis via ICS in baseline and post-treatment biopsies, if clinically indicated [ Time Frame: Up to 3 years ]
  • Total PBMC counts by flow cytometry [ Time Frame: Up to 3 years ]
  • Tumor antigen expression [ Time Frame: At screening ]
    Evaluation of pre-treatment tumor tissue for antigen expression
  • Tumor Infiltrating Lymphocytes (TILs) [ Time Frame: Up to 3 years ]
    Evaluation of tumor tissue obtained from repeat biopsy, if clinically indicated, for presence of TILs
  • T cell receptor sequencing of peripheral blood T cells before and during treatment [ Time Frame: Up to 2 years ]
  • Safety of the combination of the HS-410 and BCG [ Time Frame: Up to 1 year ]
    Phase 2 only
  • Safety of the high dose HS-410 monotherapy [ Time Frame: Up to 3 years ]
    Phase 2 only
  • Progression-free survival (PFS) [ Time Frame: Up to 3 years ]
  • Overall survival (OS) [ Time Frame: Up to 3 years ]
Not Provided
  • Tumor antigen expression analysis [ Time Frame: At screening ]
    Evaluation of pre-treatment tumor tissue for antigen expression
  • Tumor Infiltrating Lymphocytes (TILs) [ Time Frame: up to 3 years ]
    Evaluation of post-treatment tumor tissue for the presence of infiltrating T-cells
 
A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT
A Phase 1/2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response and Clinical Activity of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer Who Have Undergone Transurethral Resection of Bladder Tumor (TURBT)
This study is a two part study: Phase I and Phase II. The Phase 1 portion is an open-label, safety study. Patients will have previously received 3-6 instillations of weekly intravesical Bacillus Calmette-Guerin (BCG) induction therapy (as standard of care) followed by low dose intradermal (1*10^6 cells) HS-410 monotherapy. In Phase 2, patients will be assigned to treatment groups based on whether they will receive induction BCG in the typical post-TURBT window. If the investigator plans to administer BCG, patients will be randomized to one of three blinded (physician-patient), placebo-controlled groups and receive either intradermal placebo or low dose (1*10^6 cells) or high dose (1*10^7 cells) vesigenurtacel-L in combination with induction and maintenance intravesical BCG. If patients will not receive BCG, they will be enrolled into an open-label, non-randomized group and receive high dose (1*10^7 cells) intradermal HS-410 monotherapy.
Not Provided
Interventional
Phase 1
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Bladder Cancer
  • Biological: HS-410
    Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96
  • Biological: Placebo
    Injection containing sterile solution but no cells
  • Biological: BCG
    Vaccine derived from a live bacterium
    Other Name: Bacillus Calmette-Guerin
  • Experimental: Phase I: HS-410 Low Dose
    In the open label Phase 1 portion, HS-410 is given as 1*10^6 cells per dose for 12 weekly injections followed by 3 monthly injections.
    Intervention: Biological: HS-410
  • Experimental: Phase II: HS-410 Low-Dose Plus BCG
    In the Phase 2 portion, HS-410 is given as 1*10^6 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.
    Interventions:
    • Biological: HS-410
    • Biological: BCG
  • Experimental: Phase II: High-Dose HS-410 Plus BCG
    In the Phase 2 portion, HS-410 is given as 1*10^7 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.
    Interventions:
    • Biological: HS-410
    • Biological: BCG
  • Placebo Comparator: Phase II: Placebo Plus BCG
    In the Phase 2 portion, a placebo is given weekly for 6 weeks in combination with BCG, followed by 6 weeks of placebo alone, and then 3 courses of three once-weekly doses of placebo in combination with BCG.
    Interventions:
    • Biological: Placebo
    • Biological: BCG
  • Experimental: Phase II: High-Dose HS-410
    In the Phase II portion, if patients will not receive BCG, HS-410 is given as 1*10^7 cells per dose weekly for 12 weeks, and then 3 courses of three once-weekly doses of HS-410.
    Intervention: Biological: HS-410
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
110
April 2020
April 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically or cytologically confirmed non-muscle invasive bladder cancer [Ta, T1 or Tis (CIS)] that has been removed by transurethral resection
  • Either: (i) high-risk disease, defined as T1 and/or high-grade and/or CIS or (ii) intermediate-risk disease, defined as Ta low-grade with at least 3 of the following 4 risk factors: multiple tumors, tumor size > 3cm, early recurrence (<1 year from previous staging procedure), or recurrence with a frequency of more than once in any 12 month period
  • Not have received bacillus Calmette-Guérin (BCG) or have completed previous BCG treatment > 12 months prior to the baseline staging procedure.
  • Phase 2 Arms 1-3: Suitable to receive a 6-week course of BCG in the adjuvant setting within 6 weeks following TURBT. Phase 2 Arm 4: Suitable for monotherapy vaccine administration post-TURBT. For Phase 1 only: Has previously received 3-6 weekly doses of BCG.
  • Adequate laboratory parameters

Exclusion Criteria:

  • Human immunodeficiency virus (HIV) infection or immunodeficiency disorders, either primary or acquired
  • Infections or intercurrent illness requiring active therapy
  • Any condition requiring active steroid or other immunosuppressive therapy
  • Active malignancies within the past 12 months except negligible risk of metastasis or death treated with expected curative outcome.
  • Prostate pelvic radiation within the past 12 months
  • Significant cardiac impairment
  • Current alcohol or chemical abuse, or mental or psychiatric condition precluding protocol compliance
  • Pregnant or nursing
  • Allergy to soy, egg, or peanut products
  • Receiving another investigational agent (30 day wash-out required prior to first dose)
  • Neo-adjuvant therapy prior to baseline staging procedures for the current occurrence of non-muscle invasive bladder cancer
  • Prior treatment with a cancer vaccine for this indication
  • Prior vaccination with BCG for tuberculosis disease
  • Prior splenectomy
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT02010203
HS410-101
Yes
Not Provided
Not Provided
Heat Biologics
Heat Biologics
Not Provided
Principal Investigator: Gary Steinberg, MD University of Chicago
Heat Biologics
April 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP